Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 3, 2003 - Issue 1
Submit an article Journal homepage
103
Views
18
CrossRef citations to date
0
Altmetric
Review

Provisional diagnostic criteria for depression of Alzheimer’s disease: description and review

Jason T Olin Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Lon S Schneider Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Ira R Katz Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Barnett S Meyers Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
George S Alexopoulos Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
John C Breitner Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Martha L Bruce Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Eric D Caine Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Jeffrey L Cummings Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Davangere P Devanand Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Dilip V Jeste Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
K Ranga Rama Krishnan Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Constantine G Lyketsos Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Jeffrey M Lyness Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Peter V Rabins Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Charles F Reynolds III Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Barry W Rovner Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
David C Steffens Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
,
Jürgen Unützer Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
&
Barry D Lebowitz Aging Research Consortium, Chief, Geriatric Psychopharmacology Program, Adult and Geriatric Treatment and Preventive, Interventions Research Branch, National Institute of Mental Health, 6001 Executive Boulevard, Room 7160 MSC 9635, Bethesda, MD 20892-9635 (surface mail), Rockville, MD 20852 (express mail only), USA. [email protected]
 show all
Pages 99-106 | Published online: 10 Jan 2014

References

  • Feighner JP, Meredith CH, Stern WC, Hendrickson G, Miller LL. A double-blind study of bupropion and placebo in depression. A117. I fiychiatry141 (4), 525–529 (1984).
  • Lineberry CG, Johnston JA, Raymond RN et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed out-patients. Clin. Psychiatry51 (5), 194–199 (1990).
  • Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA. A multicenter evaluation of the efficacy and safety of 150 and 300 mghl sustained-release bupropion tablets versus placebo in depressed out- patients. Clin. Therapeutics Int. j Drug Therapy20(3), 505–516 (1998).
  • Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed out-patients. Clin. Psychiaby 58(12), 532–537 (1997).
  • Weihs KL, Settle EC Jr, Batey SR etal Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. PTchiatry61(3), 196–202 (2000).
  • Coleman CC, Cunningham LA, Foster VJ eta] Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann. Clin. PTchiatry11(4), 205–215 (1999).
  • Feighner JP, Gardner EA, Johnston JA eta]. Double-blind comparison of bupropion and fluoxetine in depressed out-patients. Clin. Psychiatry 52 (8), 329–335 (1991) .
  • Anonymous. Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. Ann. Intern. Med. 135(6), S-40 (2001).
  • Hays JT, Hurt RD, Rigotti NA etal. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann. Intern. Med. 135(6), 423–433 (2001).
  • Hurt RD, Sachs DP, Glover ED eta]. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl. .J. Med. 337(17), 1195–1202 (1997).
  • Ascher JA, Cole JO, Colin JN eta]. Bupropion: A review of its mechanism of antidepressant activity. j Clin. Psychiatry 56(9), 395–401 (1995).
  • •Good review article about bupropion's pharmacodynamic effects.
  • Cooper BR, Wang CM, Cox RF eta]. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology11,133–141 (1994).
  • Horst WD, Preskom SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. j Alièct. Disarlets 51(3), 237–254 (1998).
  • Hesse LM, Venkatakrishnan K, Court MR eta] CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metabolism Disposition 28(10), 1176–1183 (2000).
  • Goodnick PJ. Pharmacokinetics of second generation antidepressants: Bupropion. PTchopharmacol Bull. 27(4), 513–519 (1991).
  • Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ. Antidepressant profile of bupropion and three metabolites in mice. Phatmacopsychiatry23(4), 187–194 (1990).
  • Perumal AS, Smith TM, Suckow RF, Cooper TB. Effect of plasma from patients containing bupropion and its metabolites on the uptake of noradrenaline. Neurophatmacology25(2), 199–202 (1986).
  • Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression: I. Biochemical effects and clinical response. Arch. Gen Psychiatry 45(2), 139–143 (1988).
  • Preskom SH. Antidepressant response and plasma concentrations of bupropion.Clin. Psychiatry 44, 137–139 (1983).
  • Preskom SH, Katz SE. Bupropion plasma levels: Intraindividual and interindividual variability. Ann. Clin. PTchiatryl (1), 59–61(1989).
  • Casat CD, Pleasants DZ, Schroeder DH, Parler DW. Bupropion in children with attention deficit disorder. Psychophatmacol Bull. 25(2), 198–201 (1989).
  • Simeon JG, Ferguson FIB, Van Wyck Fleet J. Bupropion effects in attention deficit and conduct disorders. Can. j Psychiatry — Revue Canadienne de Psychiatrie 31 (6), 581–585 (1986).
  • Golden RN, DeVane CL, Laizure SC etal. Bupropion in depression: II. The role of metabolites in clinical outcome. Arch. Gen Psychiatry 45(2), 145–149 (1988).
  • Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: Results of three clinical trials. Clin. Therapeutics Int. Drug Therapy21 (3), 454–463 (1999).
  • Settle EC. Bupropion sustained release: side effect profile. j Clin. Psychiatry 4,32–36 (1998).
  • •Good review about the relative tolerability of bupropion's SR and IR forms.
  • Davidson J. Seizures and bupropion: a review. Clin. Psychiatry50(7), 256–261 (1989).
  • GlaxoSmithKline I. Product Information: Wellbutrin SR (bupropion hydrochloride) sustained-release tablets. Information on File, 1–22 (2000).
  • Dunner DL, Zisook S, Billow AA eta] A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. j Clin. Psychiatry 59(7), 366–373 (1998).
  • Brown ES, Dilsaver SC, Shoaib AM, Swann AC. Depressive mania: response of residual depression to bupropion. Biol. Psychiatry 35(7), 493–494 (1994).
  • Goren JL, Levin GM. Mania with bupropion: a dose-related phenomenon? Ann. Phatmacother. 34(5), 619–621 (2000).
  • Masand P, Stem TA. Bupropion and secondary mania. Is there a relationship? Ann. Clin. fiychiatry5(4), 271–274 (1993).
  • Zubieta JK, Demitrack MA. Possible bupropion precipitation of mania and a mixed affective state. j Clin. PTchopharmacologyll (5), 327–328 (1991).
  • Stoll AL, Mayer PV, Kolbrener M eta]. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Arn. PTchiatry 151 (11), 1642–1645 (1994).
  • Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The Expert Consensus Guidelines for treating depression in bipolar disorder. j Clin. PTchiatry59 (Suppl. 4), 73–79 (1998).
  • Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol. fiychiatry 48 (6), 558–572 (2000).
  • Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. Ann. Pharmacotherapy27 (4), 431–433 (1993).
  • Barrickman LL, Perry PJ, Allen AJ eta] Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. jAm. Acad. Child Adolesc. Psychiatry 34 (5), 649–657 (1995) .
  • Conners CK, Casat CD, Gualtieri CT eta]. Bupropion hydrochloride in attention deficit disorder with hyperactivity. j Am. Acad. Child Adolesc. PTchiatry35(10), 1314–1321 (1996).
  • Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ. Bupropion SR in the treatment of adolescent depression. In: Child Section of the 40th Annual National Institutes of Mental Health New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, USA, May 30—June 2 (2000).
  • Daviss WB, Bentivoglio P, Racusin R etal Bupropion sustained release in adolescents with comorbid attention-deficit/ hyperactivity disorder and depression. Arn. Acad. Child Adolesc. Psychiatry 40 (3), 307–314 (2001).
  • Spencer T, Biederman J, Steingard R, Wilens T Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. I Am. Acad. Child Adolesc. PTchiatry32 (1), 211–214 (1993).
  • Jacobsen LK, Chappell P, Woolston JL. Bupropion and compulsive behavior. I Am.
  • •• Acad. Child Adolesc. Bychiatry33(1), 143–144 (1994).
  • Branch RA. Characteristics of drug disposition during childhood. In:Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disotylers. Gershon S (Ed.). Brunner/Mazel Publishers, New York, NY, USA (1994).
  • Posner J, Bye A, Dean K, Peck AW, Whiteman PD. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur.j Clin. Pharmacology29(1), 97–103 (1985).
  • Daviss WB, Perel J, Rudolph G et al Pharmacokinetics of bupropion SR in adolescent patients. In: 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, USA, October 22–27 (2002).
  • Sweet RA, Pollock BG, Kirshner M et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J. Clin. Phaimacology35 (9), 876–884 (1995).
  • Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metabolism Disposition 29(2), 100–102 (2001).
  • Nemeroff CB, DeVane CL, Pollock BG. New antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153,311–320 (1996).
  • Ketter TA, Jenkins JB, Schroeder DH etal. Carbamazepine but not valproate induces bupropion metabolism. J. Clin. Bychopharmacology 15 (5), 327–333 (1995).
  • •Good general review article about the epidemiology, assessment, treatment and course of ADHD in children and adolescents.
  • Cantwell DR Attention deficit disorder: a review of the past 10 years. J. A117. Acad. Child Adolesc. Ptychiatry35 (8), 978–987 (1996).
  • •Summarizes literature about the role of catecholarnines in the pathophysiology of ADHD
  • Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. Am. Acad. Child Adolesc. Psychiatry 35(3), 264–272 (1996).
  • ••Excellent review article summarizing therange of pharmacological treatments for ADHD and their level of empirical support.
  • Spencer T, Biederman J, Wilens T etal. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Am. Acad. Child Adolesc. Ptychiatry35 (4), 409–432 (1996).
  • •Reviews empirical support for bupropion for ADHD across lifespan.
  • Cantwell DP. ADHD through the lifespan: the role of bupropion in treatment. j Clin. BychMtry59\(Suppl. 4), 92–94 (1998).
  • Wilens TE, Spencer TJ, Biederman J etal. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am. Bychiatry158 (2), 282–288 (2001).
  • ••Good review article about ADHDcomorbidity, with some practical clinical suggestions.
  • Pliszka SR. Comorbidity of attention- deficit/hyperactivity disorder with psychiatric disorder: an overview. J. Clin. BychMtry59\(Suppl. 7), 50–58 (1998).
  • •Another good review article about ADHD comorbidity.
  • Spencer T, Biederman J, Wilens T Attention-deficit/hyperactivity disorder and comorbidity. Pediatric Clin. N Am. 46(5), 915–927 (1999).
  • ••Reviews ADHD comorbidity from thestandpoint of unanswered empirical questions.
  • Jensen PS, Martin D, Cantwell DP Comorbidity in ADHD: implications for research, practice and DSM-V jAm. Acad. Child Adolesc. Psychiatry36(8), 1065–1079 (1997).
  • Biederman J, Faraone SV, Keenan K etal. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch. Gen. BychMtry 49(9), 728–738 (1992).
  • Biederman J, Faraone S, Mick E, Moore P, Lelon E. Child Behavior Checklist findings further support comorbidity between ADHD and major depression in a referred sample. J. A117. Acad. Child Adolesc. fiychMtry35(6), 734–742 (1996).
  • Birmaher B, Ryan ND, Williamson DE etal. Childhood and adolescent depression: A review of the past 10 years, Part I.j Am. Acad. Child Adolesc. Psychiatry 35 (11), 1427–1439 (1996).
  • Biederman J. Attention-deficit/ hyperactivity disorder: a lifespan perspective. J. Clin. Psychiatry59 (Suppl. 7), 4–16 (1998).
  • Zomberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J. Clin. Psychophatmacology 13(6), 397–408 (1993).
  • Wilens T, Prince J, Spencer T etal. Bupropion SR for ADHD in adults with bipolar disorder and ADHD: preliminary data. In: The 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, USA, October 24–29 (2000).
  • Goodnick PJ, Dominguez RA, DeVane CL, Bowden CL. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol. Psychiatry 44(7), 629–632 (1998).
  • Pliszka SR. Effect of anxiety on cognition, behavior and stimulant response in ADHD. jAm. Acad. Child Adolesc. Psychiatry 28(6), 882–887 (1989).
  • Trivedi MH, Rush AJ, Carmody TJ. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J. Clin. Psychiatry 62(10), 776–781 (2001).
  • Rush AJ, Trivedi MH, Carmody TJ etal. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 25 (1), 131–138 (2001).
  • Rush AJ, Batey SR, Donahue RM etal Does pretreatment anxiety predict response to either bupropion SR or sertraline? Affect. Disotylety 64(1), 81–87 (2001).
  • Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J. Clin. Bychopharmacology3(1), 28–31 (1983).
  • Emmanuel NP, Pollack MET, Morton A etal Bupropion sustained release in the treatment of panic disorder. In: Poster presented at the New Clinical Drug Evaluation Unit Program (NCDEU), Boca Raton, FL, USA, June 10–13 (2001).
  • Emmanuel NP, Brawman-Mintzer 0, Morton WA etal Bupropion-SR in treatment of social phobia. Depression Anxiety 12 (2), 111–113 (2000) .
  • Canive JM, Clark RD, Calais LA, Qualls C, Tuason VB. Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J. Clin. Bychopharmacology 18(5), 379–383 (1998).
  • Almai AM, Brouette T, Jetty P et al Bupropion sustained release in the treatment of civilian post traumatic stress disorder. In: Poster Presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, USA, May 13–18 (2000).
  • Nutt DJ. Addiction: brain mechanisms and their treatment implications. Lancet 347(8993), 31–36 (1996).
  • Robbins TW, Granon S, Muir JL et al. Neural systems underlying arousal and attention. Implications for drug abuse. Ann. NY Acad. Sc]. 846,222–237 (1998).
  • Solhkhan R, Wilens T, Prince J. Bupropion substained release for substance abuse, ADHD and mood disorders in adolescents. In: Poster Presented at the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA, May 5–10 (2001).
  • Margolin A, Kosten T, Petrakis I, Avants SK. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch. Gen. PFhiatry48(1), 87 (1991).
  • Margolin A, Kosten TR, Avants SK etal. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Dependence 40 (2), 125–131 (1995).
  • ••First of two papers developed by theconsensus panel of experts with the Texas Medical Algorithms Project, this paper provides treatment algorithms and their empirical support in the pharmacological management of ADHD and it comorbid conditions, including major depression/ anxiety, tics and intermittent explosive disorders.
  • Pliszka SR, Greenhill LL, Crimson ML et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. J. Am. Acad. Child Adolesc. Psychiatry 39 (7), 908–919 (2000).
  • Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J. Child Adolesc. Bychophatmacology3(1),1–10 (1993).
  • Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin re-uptake inhibitors and psychostimulants in children, adolescents and adults: a case series. J. Child Adolesc. Psychopharmacology6(3), 165–175 (1996).
  • Michelson D, Faries D, Wernicke J eta]. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5), E83 (2001).
  • Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J. Child Adolesc. Psychopharmacology6(4), 241–250 (1996).
  • Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen Psychiatry54(11), 1031–1037 (1997).
  • Keller MB, Ryan ND, Strober M eta] Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. jAm. Acad. Child Adolesc. Psychiatry 40(7), 762–772 (2001).
  • Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J. Clin. Psychiatry59\(Suppl. 18), 23–29 (1998).
  • Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J. Clin. Bychiatry59\(Suppl. 4), 5–14 (1998).

Websites

  • www.gsk.com/products/assets/ us wellbutrinsr.pdf Glaxo SmithKline, the manufacturer of both forms of bupropion (VVellbutrin® and Wellbutrin SR® as well as Zyban).
  • •• Summarizes current pharrnacokinetic and pharrnacodynamic information, approved indications, side effects, potential interactions with other medications and dosing recommendations for these drugs.
  • www.mca.gov.uk
  • ••This website for the UK MCA providesupdated information about adverse events associated with bupropion and other drugs and clinician guidelines regarding the safe use of these medications.
  • www.chadd.org
  • •This site, produced by Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD), summarizes current empirical support for the diagnosis and treatment of ADHD and has good sections on comorbid disorders with ADHD.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.